Molecular and genetic markers in the local-regional management of breast cancer

被引：22

作者：

Haffty, BG ^{[1
]}

机构：

[1] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA

来源：

SEMINARS IN RADIATION ONCOLOGY | 2002年 / 12卷 / 04期

关键词：

D O I：

10.1053/srao.2002.35252

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The clinical application of molecular markers in the diagnosis, staging, and management of breast cancer continues to expand. Although the use of molecular markers in local-regional disease does not approach the level of their application in the systemic management of breast cancer, a growing body of literature supports the potential for molecular and genetic factors in clinical decision making regarding the local-regional management of breast cancer. As with conventional clinical and histopathologic factors, data regarding molecular and genetic factors as they relate to local-regional relapse may be conflicting and are subject to the usual limitations of predominantly retrospective studies. There are, however, some consistent data suggesting associations between local-regional control of disease and several molecular markers, including hormone receptor status, HER2/neu, p53, proliferative markers, and others. Interpretion of these data and how to use this information in clinical practice remains challenging. The available literature regarding the use of genetic and molecular markers in the local-regional management of breast cancer is summarized in this review. Copyright 2002, Elsevier Science (USA). All rights reserved.

引用

页码：329 / 340

页数：12

共 75 条

[1] C-erbB-2 overexpression and survival in early onset breast cancer [J].

Agrup, M ;

Stäl, O ;

Olsen, K ;

Wingren, S .

BREAST CANCER RESEARCH AND TREATMENT, 2000, 63 (01) :23-29

[2]

Amornmarn R, 2000, ANN CLIN LAB SCI, V30, P33

[3] Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. [J].

Bartelink, H ;

Horiot, J ;

Poortmans, P ;

Struikmans, H ;

Van den Bogaert, W ;

Barillot, I ;

Fourquet, A ;

Borger, J ;

Jager, J ;

Hoogenraad, W ;

Collette, L ;

Pierart, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (19) :1378-1387

[4] PROGNOSTIC-SIGNIFICANCE OF P53 OVEREXPRESSION IN PRIMARY BREAST-CANCER - A NOVEL LUMINOMETRIC IMMUNOASSAY APPLICABLE ON STEROID-RECEPTOR CYTOSOLS [J].

BORG, A ;

LENNERSTRAND, J ;

STENMARKASKMALM, M ;

FERNO, M ;

BRISFORS, A ;

OHRVIK, A ;

STAL, O ;

KILLANDER, D ;

LANE, D ;

BRUNDELL, J .

BRITISH JOURNAL OF CANCER, 1995, 71 (05) :1013-1017

[5] Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome [J].

Bougeard, G ;

Limacher, JM ;

Martin, C ;

Charbonnier, F ;

Killian, A ;

Delattre, O ;

Longy, M ;

Jonveaux, P ;

Fricker, JP ;

Stoppa-Lyonnet, D ;

Flaman, JM ;

Frébourg, T .

JOURNAL OF MEDICAL GENETICS, 2001, 38 (04) :253-256

[6] Molecular profiling of breast cancer: portraits but not physiognomy [J].

Brenton, JD ;

Aparicio, SAJR ;

Caldas, C .

BREAST CANCER RESEARCH, 2001, 3 (02) :77-80

[7] Thymidine kinase as a proliferative marker:: Clinical relevance in 1,692 primary breast cancer patients [J].

Broët, P ;

Romain, S ;

Daver, A ;

Ricolleau, G ;

Quillien, V ;

Rallet, A ;

Asselain, B ;

Martin, PM ;

Spyratos, F .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) :2778-2787

[8]

Buchholz TA, 1999, RADIAT ONCOL INVESTI, V7, P55, DOI 10.1002/(SICI)1520-6823(1999)7:2<55::AID-ROI1>3.0.CO

[9]

2-#

[10] The association of HER-2/neu amplification with breast cancer recurrence [J].

Carr, JA ;

Havstad, S ;

Zarbo, RJ ;

Divine, G ;

Mackowiak, P ;

Velanovich, V .

ARCHIVES OF SURGERY, 2000, 135 (12) :1469-1474

← 1 2 3 4 5 6 7 8 →